{
  "lastVerified": "2026-11-03",
  "currency": "USD",
  "notes": "US prices only. Self-pay = the manufacturer's own cash price for patients paying without insurance. List price = wholesale acquisition cost (WAC) published by the manufacturer, before rebates or discounts. Every figure was copied from the source URL listed for it. 'Not published' means we could not find an official figure.",
  "medications": [
    {
      "id": "wegovy-pill",
      "brand": "Wegovy pill",
      "generic": "semaglutide tablets",
      "manufacturer": "Novo Nordisk",
      "form": "Daily tablet",
      "group": "weight",
      "approvedUse": "Chronic weight management (see prescribing information for full indications)",
      "listPrice": "$1,349.02 per package of 30 tablets (all strengths)",
      "listPriceSource": "https://www.novopricing.com/wegovy.html",
      "selfPayFrom": 149,
      "selfPay": [
        {
          "dose": "1.5 mg",
          "price": "$149"
        },
        {
          "dose": "4 mg",
          "price": "$199"
        },
        {
          "dose": "9 mg",
          "price": "$299"
        },
        {
          "dose": "25 mg",
          "price": "$299"
        }
      ],
      "selfPayUnit": "per month (30 tablets), NovoCare Pharmacy",
      "selfPaySource": "https://www.novocare.com/pharmacy.html",
      "insured": "As little as $25/month with commercial coverage (max savings $100/month); government beneficiaries excluded. Eligible Medicare Part D enrollees: $50/month copay through the Medicare GLP-1 Bridge.",
      "notes": "Novo Nordisk says the list price of Wegovy 25 mg tablets will drop to $675 from January 1, 2027.",
      "sources": [
        {
          "label": "NovoCare Pharmacy self-pay prices",
          "url": "https://www.novocare.com/pharmacy.html"
        },
        {
          "label": "Novo Nordisk list price (Wegovy)",
          "url": "https://www.novopricing.com/wegovy.html"
        },
        {
          "label": "Novo Nordisk list-price reduction, Feb 24, 2026",
          "url": "https://www.novonordisk-us.com/media/press-releases/novo-nordisk-lowers-wegovy-ozempic-list-price.html"
        },
        {
          "label": "CMS: Medicare GLP-1 Bridge",
          "url": "https://www.cms.gov/medicare/coverage/prescription-drug-coverage/medicare-glp-1-bridge/information-part-d-plans"
        }
      ],
      "lastVerified": "2026-11-03"
    },
    {
      "id": "wegovy-injection",
      "brand": "Wegovy injection",
      "generic": "semaglutide injection",
      "manufacturer": "Novo Nordisk",
      "form": "Weekly pen",
      "group": "weight",
      "approvedUse": "Chronic weight management (see prescribing information for full indications)",
      "listPrice": "$1,349.02 per package (all strengths, including Wegovy HD 7.2 mg)",
      "listPriceSource": "https://www.novopricing.com/wegovy.html",
      "selfPayFrom": 199,
      "selfPay": [
        {
          "dose": "0.25 mg or 0.5 mg, first 2 monthly fills (new patients, through Dec 31, 2026)",
          "price": "$199"
        },
        {
          "dose": "0.25 mg to 2.4 mg (standard price)",
          "price": "$349"
        },
        {
          "dose": "Wegovy HD 7.2 mg",
          "price": "$399"
        }
      ],
      "selfPayUnit": "per month (1 box of 4 pens), NovoCare Pharmacy",
      "selfPaySource": "https://www.novocare.com/pharmacy.html",
      "insured": "As little as $25/month with commercial coverage (max savings $100/month); government beneficiaries excluded. Eligible Medicare Part D enrollees: $50/month copay through the Medicare GLP-1 Bridge.",
      "notes": "Novo Nordisk says the list price of Wegovy 2.4 mg injection will drop to $675 from January 1, 2027. Self-pay prices are separate from list price.",
      "sources": [
        {
          "label": "NovoCare Pharmacy self-pay prices",
          "url": "https://www.novocare.com/pharmacy.html"
        },
        {
          "label": "Novo Nordisk list price (Wegovy)",
          "url": "https://www.novopricing.com/wegovy.html"
        },
        {
          "label": "Novo Nordisk list-price reduction, Feb 24, 2026",
          "url": "https://www.novonordisk-us.com/media/press-releases/novo-nordisk-lowers-wegovy-ozempic-list-price.html"
        },
        {
          "label": "CMS: Medicare GLP-1 Bridge",
          "url": "https://www.cms.gov/medicare/coverage/prescription-drug-coverage/medicare-glp-1-bridge/information-part-d-plans"
        }
      ],
      "lastVerified": "2026-11-03"
    },
    {
      "id": "zepbound-kwikpen",
      "brand": "Zepbound KwikPen",
      "generic": "tirzepatide injection",
      "manufacturer": "Eli Lilly",
      "form": "Weekly multi-dose pen",
      "group": "weight",
      "approvedUse": "Chronic weight management; moderate to severe obstructive sleep apnea in adults with obesity",
      "listPrice": "$499 to $1,086.37 per fill (range across Zepbound products)",
      "listPriceSource": "https://pricinginfo.lilly.com/zepbound",
      "selfPayFrom": 299,
      "selfPay": [
        {
          "dose": "2.5 mg",
          "price": "$299"
        },
        {
          "dose": "5 mg",
          "price": "$399"
        },
        {
          "dose": "7.5 mg",
          "price": "$449 with on-time refill; otherwise $499"
        },
        {
          "dose": "10 mg, 12.5 mg, 15 mg",
          "price": "$449 with on-time refill; otherwise $699"
        }
      ],
      "selfPayUnit": "per month (28 days; 1 KwikPen), LillyDirect or with the Zepbound self-pay savings card at retail pharmacies",
      "selfPaySource": "https://www.lilly.com/lillydirect/zepbound",
      "insured": "Eligible Medicare Part D enrollees: $50/month copay through the Medicare GLP-1 Bridge (KwikPen). For commercial coverage, see the single-dose pen note.",
      "notes": "$449 requires the Zepbound Journey Program: refill within 45 days of the previous delivery. Pen needles are bought separately. Self-pay savings card valid through Dec 31, 2026.",
      "sources": [
        {
          "label": "LillyDirect: Zepbound",
          "url": "https://www.lilly.com/lillydirect/zepbound"
        },
        {
          "label": "Zepbound savings and terms",
          "url": "https://zepbound.lilly.com/savings"
        },
        {
          "label": "Lilly pricing information (Zepbound)",
          "url": "https://pricinginfo.lilly.com/zepbound"
        },
        {
          "label": "CMS: Medicare GLP-1 Bridge",
          "url": "https://www.cms.gov/medicare/coverage/prescription-drug-coverage/medicare-glp-1-bridge/information-part-d-plans"
        }
      ],
      "lastVerified": "2026-11-03"
    },
    {
      "id": "zepbound-vial",
      "brand": "Zepbound single-dose vial",
      "generic": "tirzepatide injection",
      "manufacturer": "Eli Lilly",
      "form": "Weekly vial (draw up with syringe)",
      "group": "weight",
      "approvedUse": "Chronic weight management; moderate to severe obstructive sleep apnea in adults with obesity",
      "listPrice": "$499 to $1,086.37 per fill (range across Zepbound products)",
      "listPriceSource": "https://pricinginfo.lilly.com/zepbound",
      "selfPayFrom": 299,
      "selfPay": [
        {
          "dose": "2.5 mg",
          "price": "$299"
        },
        {
          "dose": "5 mg",
          "price": "$399"
        },
        {
          "dose": "7.5 mg",
          "price": "$449 with on-time refill; otherwise $499"
        },
        {
          "dose": "10 mg, 12.5 mg, 15 mg",
          "price": "$449 with on-time refill; otherwise $699"
        }
      ],
      "selfPayUnit": "per month (28 days; 4 vials), LillyDirect only",
      "selfPaySource": "https://www.lilly.com/lillydirect/zepbound",
      "insured": "Vials are a self-pay option. With commercial coverage, Lilly's savings card lets you pay as low as $25 for a 1- or 3-month supply of the Zepbound single-dose pen (subject to monthly and annual limits; government beneficiaries excluded).",
      "notes": "$449 requires the Zepbound Journey Program: refill within 45 days. Needles and syringes are bought separately.",
      "sources": [
        {
          "label": "LillyDirect: Zepbound",
          "url": "https://www.lilly.com/lillydirect/zepbound"
        },
        {
          "label": "Zepbound savings and terms",
          "url": "https://zepbound.lilly.com/savings"
        },
        {
          "label": "Lilly pricing information (Zepbound)",
          "url": "https://pricinginfo.lilly.com/zepbound"
        }
      ],
      "lastVerified": "2026-11-03"
    },
    {
      "id": "foundayo",
      "brand": "Foundayo",
      "generic": "orforglipron tablets",
      "manufacturer": "Eli Lilly",
      "form": "Daily tablet",
      "group": "weight",
      "approvedUse": "Chronic weight management (FDA approved April 1, 2026)",
      "listPrice": "$649.00 per 30-day supply",
      "listPriceSource": "https://pricinginfo.lilly.com/foundayo",
      "selfPayFrom": 149,
      "selfPay": [
        {
          "dose": "0.8 mg",
          "price": "$149"
        },
        {
          "dose": "2.5 mg",
          "price": "$149 through Dec 31, 2026 (regular $199)"
        },
        {
          "dose": "5.5 mg",
          "price": "$199 through Dec 31, 2026 (regular $299)"
        },
        {
          "dose": "9 mg",
          "price": "$299"
        },
        {
          "dose": "14.5 mg, 17.2 mg",
          "price": "$299 with on-time refill; otherwise $349"
        }
      ],
      "selfPayUnit": "per month (30 days), LillyDirect or with the Foundayo self-pay savings card",
      "selfPaySource": "https://foundayo.lilly.com/coverage-savings",
      "insured": "As little as $25/month with commercial coverage (max savings $100/month, $1,000/year); government beneficiaries excluded. Eligible Medicare Part D enrollees: $50/month through the Medicare GLP-1 Bridge.",
      "notes": "$299 for 14.5 mg and 17.2 mg requires a refill within 45 days of the previous delivery.",
      "sources": [
        {
          "label": "Foundayo coverage and savings",
          "url": "https://foundayo.lilly.com/coverage-savings"
        },
        {
          "label": "Lilly pricing information (Foundayo)",
          "url": "https://pricinginfo.lilly.com/foundayo"
        },
        {
          "label": "CMS: Medicare GLP-1 Bridge",
          "url": "https://www.cms.gov/medicare/coverage/prescription-drug-coverage/medicare-glp-1-bridge/information-part-d-plans"
        }
      ],
      "lastVerified": "2026-11-03"
    },
    {
      "id": "saxenda",
      "brand": "Saxenda",
      "generic": "liraglutide injection",
      "manufacturer": "Novo Nordisk",
      "form": "Daily pen",
      "group": "weight",
      "approvedUse": "Chronic weight management in adults and children 12+ (see prescribing information)",
      "listPrice": "$1,349.02 per package of 5 pens",
      "listPriceSource": "https://www.novopricing.com/saxenda.html",
      "selfPayFrom": null,
      "selfPay": [],
      "selfPayUnit": "Not published (no NovoCare Pharmacy self-pay price)",
      "selfPaySource": "https://www.novocare.com/obesity/products/saxenda.html",
      "insured": "Coverage depends on your plan.",
      "notes": "Novo Nordisk is discontinuing Saxenda, with last shipments to wholesalers in late January 2027. The company says this is not due to safety or quality concerns.",
      "sources": [
        {
          "label": "NovoCare: Saxenda (discontinuation notice)",
          "url": "https://www.novocare.com/obesity/products/saxenda.html"
        },
        {
          "label": "Novo Nordisk list price (Saxenda)",
          "url": "https://www.novopricing.com/saxenda.html"
        }
      ],
      "lastVerified": "2026-11-03"
    },
    {
      "id": "liraglutide-generic",
      "brand": "Generic liraglutide (generic Saxenda)",
      "generic": "liraglutide injection",
      "manufacturer": "Teva (first generic)",
      "form": "Daily pen",
      "group": "weight",
      "approvedUse": "Weight management in adults with obesity, or overweight with weight-related conditions, and children 12–17 with obesity (per Teva)",
      "listPrice": "Not published",
      "listPriceSource": null,
      "selfPayFrom": null,
      "selfPay": [],
      "selfPayUnit": "Not published",
      "selfPaySource": null,
      "insured": "Coverage depends on your plan.",
      "notes": "FDA approved and launched August 28, 2025. Teva did not publish a price. Pharmacy prices vary.",
      "sources": [
        {
          "label": "Teva press release, Aug 28, 2025",
          "url": "https://ir.tevapharm.com/news-and-events/press-releases/press-release-details/2025/Teva-Announces-FDA-Approval-and-Launch-of-Generic-Saxenda-liraglutide-injection--First-Generic-GLP-1-Indicated-for-Weight-Loss/default.aspx"
        }
      ],
      "lastVerified": "2026-11-03"
    },
    {
      "id": "ozempic-injection",
      "brand": "Ozempic injection",
      "generic": "semaglutide injection",
      "manufacturer": "Novo Nordisk",
      "form": "Weekly pen",
      "group": "diabetes",
      "approvedUse": "Type 2 diabetes (not approved for weight management)",
      "listPrice": "$1,027.51 per 1-pen package",
      "listPriceSource": "https://www.novopricing.com/ozempic.html",
      "selfPayFrom": 199,
      "selfPay": [
        {
          "dose": "0.25 mg or 0.5 mg, first 2 monthly fills (new patients, through Dec 31, 2026)",
          "price": "$199"
        },
        {
          "dose": "0.25 mg, 0.5 mg, 1 mg (standard price)",
          "price": "$349"
        },
        {
          "dose": "2 mg",
          "price": "$499"
        }
      ],
      "selfPayUnit": "per month (1 pen), NovoCare Pharmacy",
      "selfPaySource": "https://www.novocare.com/pharmacy.html",
      "insured": "As little as $25/month with commercial coverage (max savings $100/month); government beneficiaries excluded.",
      "notes": "Novo Nordisk says the list price of Ozempic 0.5 mg, 1 mg and 2 mg will drop to $675 from January 1, 2027.",
      "sources": [
        {
          "label": "NovoCare Pharmacy self-pay prices",
          "url": "https://www.novocare.com/pharmacy.html"
        },
        {
          "label": "Novo Nordisk list price (Ozempic)",
          "url": "https://www.novopricing.com/ozempic.html"
        },
        {
          "label": "Novo Nordisk list-price reduction, Feb 24, 2026",
          "url": "https://www.novonordisk-us.com/media/press-releases/novo-nordisk-lowers-wegovy-ozempic-list-price.html"
        }
      ],
      "lastVerified": "2026-11-03"
    },
    {
      "id": "ozempic-pill",
      "brand": "Ozempic pill (replaces Rybelsus in the US)",
      "generic": "semaglutide tablets",
      "manufacturer": "Novo Nordisk",
      "form": "Daily tablet",
      "group": "diabetes",
      "approvedUse": "Type 2 diabetes (not approved for weight management)",
      "listPrice": "$1,027.51 per package of 30 tablets (1.5 mg, 4 mg, 9 mg)",
      "listPriceSource": "https://www.novopricing.com/ozempic.html",
      "selfPayFrom": 149,
      "selfPay": [
        {
          "dose": "1.5 mg",
          "price": "$149"
        },
        {
          "dose": "4 mg",
          "price": "$199"
        },
        {
          "dose": "9 mg",
          "price": "$299"
        }
      ],
      "selfPayUnit": "per month (30 tablets), NovoCare Pharmacy",
      "selfPaySource": "https://www.novocare.com/pharmacy.html",
      "insured": "As little as $25/month with commercial coverage (max savings $100/month); government beneficiaries excluded.",
      "notes": "Available in the US from May 4, 2026, replacing Rybelsus. Tablet strengths differ from Rybelsus and are not interchangeable milligram for milligram.",
      "sources": [
        {
          "label": "NovoCare Pharmacy self-pay prices",
          "url": "https://www.novocare.com/pharmacy.html"
        },
        {
          "label": "Novo Nordisk list price (Ozempic)",
          "url": "https://www.novopricing.com/ozempic.html"
        },
        {
          "label": "Novo Nordisk: Ozempic pill US availability, May 1, 2026",
          "url": "https://www.novonordisk-us.com/media/press-releases/ozempic-pill-us-availability-type-2-diabetes.html"
        }
      ],
      "lastVerified": "2026-11-03"
    },
    {
      "id": "mounjaro",
      "brand": "Mounjaro",
      "generic": "tirzepatide injection",
      "manufacturer": "Eli Lilly",
      "form": "Weekly single-dose pen",
      "group": "diabetes",
      "approvedUse": "Type 2 diabetes (not approved for weight management)",
      "listPrice": "$1,112.16 per fill",
      "listPriceSource": "https://pricinginfo.lilly.com/mounjaro",
      "selfPayFrom": 499,
      "selfPay": [
        {
          "dose": "All doses (2.5 mg to 15 mg)",
          "price": "$499"
        }
      ],
      "selfPayUnit": "per month, LillyDirect",
      "selfPaySource": "https://www.lilly.com/lillydirect/mounjaro",
      "insured": "As little as $25 for a 1- to 3-month fill with commercial coverage (max savings $150/month, $1,950/year); $499/month if your commercial plan does not cover Mounjaro. Government beneficiaries excluded.",
      "notes": "Not part of the Medicare GLP-1 Bridge, which covers weight-management drugs only.",
      "sources": [
        {
          "label": "LillyDirect: Mounjaro",
          "url": "https://www.lilly.com/lillydirect/mounjaro"
        },
        {
          "label": "Mounjaro savings and resources",
          "url": "https://mounjaro.lilly.com/savings-resources"
        },
        {
          "label": "Lilly pricing information (Mounjaro)",
          "url": "https://pricinginfo.lilly.com/mounjaro"
        }
      ],
      "lastVerified": "2026-11-03"
    }
  ],
  "compounded": {
    "summary": "Compounded semaglutide, tirzepatide and liraglutide are not FDA-approved. The FDA does not review compounded drugs for safety, effectiveness or quality before they are marketed. There is no official price list; prices are set by each telehealth company or pharmacy.",
    "study": "A peer-reviewed study of websites selling compounded GLP-1s (data collected July–September 2024) found these median first-month prices, including discounts.",
    "rows": [
      {
        "drug": "Compounded semaglutide",
        "median": "$231",
        "range": "$189–$294 (IQR)"
      },
      {
        "drug": "Compounded tirzepatide",
        "median": "$330",
        "range": "$275–$399 (IQR)"
      },
      {
        "drug": "Compounded liraglutide",
        "median": "$248",
        "range": "$223–$274 (IQR)"
      }
    ],
    "caveat": "These are 2024 figures from one study and are shown for context only. They are not current prices and are not updated by our daily check.",
    "sources": [
      {
        "label": "JAMA Health Forum (2025): Online Advertising of Compounded GLP-1 Receptor Agonists",
        "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC11742527/"
      },
      {
        "label": "FDA: concerns with unapproved GLP-1 drugs used for weight loss",
        "url": "https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss"
      }
    ]
  },
  "medicareBridge": {
    "summary": "From July 1, 2026 to December 31, 2027, eligible Medicare Part D enrollees can get Wegovy (injection and tablets), the Zepbound KwikPen and Foundayo for weight management for a $50 monthly copay.",
    "source": "https://www.cms.gov/medicare/coverage/prescription-drug-coverage/medicare-glp-1-bridge/information-part-d-plans"
  },
  "changelog": [
    {
      "date": "2026-11-03",
      "change": "Tracker launched. All prices checked against manufacturer and CMS pages."
    }
  ]
}